Vancomycin 125mg

DRUG3 trials

Conditions

Clostridium Difficile InfectionDiffuse Large B Cell Lymphoma (DLBCL)Diffuse Large B Cell Lymphoma RefractoryDiffuse Large B Cell Lymphoma RelapsedLarge B Cell LymphomaMetastatic Castration-Resistant Prostate Cancer (mCRPC)Non Hodgkin Lymphoma (NHL)Vancomycin Resistant Enterococci Infection

Phase 1

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

RecruitingNCT06126731

Institute of Cancer Research, United KingdomMetastatic Castration-Resistant Prostate Cancer (mCRPC)

Start: 2023-11-02End: 2027-06-30Target: 39Updated: 2025-11-24

Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

Not yet recruitingNCT07478848

Abramson Cancer Center at Penn MedicineDiffuse Large B Cell Lymphoma (DLBCL), Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed +2

Start: 2026-04-07End: 2029-01-01Target: 14Updated: 2026-03-18

Phase 2

Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients

RecruitingNCT07221370

Riverside University Health System Medical CenterClostridium Difficile Infection, Vancomycin Resistant Enterococci Infection

Start: 2024-10-21End: 2026-12-31Target: 176Updated: 2025-11-07

Vancomycin 125mg

Sponsors

Conditions

Phase 1

Phase 2